References

1.
Ikkala E. Haemophilia. A study of its laboratory, clinical, genetic and social aspects based on known haemophiliacs in Finland. Le Scalpel 1960;12:1–144.
2.
Patek AJ, Taylor FHL, et al. Hemophilia. II. Some properties of a substance obtained from normal human plasma effective in accelerating the coagulation of hemophilic blood. The Journal of Clinical Investigation 1937;16:113–24. doi:10.1172/jci100829.
3.
Nilsson IM, Blombäck M, Jorpes E, Blombäck B, Johansson S. v. Willebrand’s Disease and its Correction with Human Plasma Fraction 1‐0. Acta Medica Scandinavica 1957;159:179–88. doi:10.1111/j.0954-6820.1957.tb00123.x.
4.
Ahlberg Å, Nilsson IM, Bauer GCH. Use of Antihemophilic Factor (Plasma Fraction I-0) during Correction of Knee-Joint Deformities in Hemophilia A: Report of Three Cases Including One Osteotomy. The Journal of Bone & Joint Surgery 1965;47:323–32. doi:10.2106/00004623-196547020-00009.
5.
Mannucci PM. Back to the future: A recent history of haemophilia treatment. Haemophilia 2008;14:10–8. doi:10.1111/j.1365-2516.2008.01708.x.
6.
Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty‐five years’ experience of prophylactic treatment in severe haemophilia A and B. Journal of Internal Medicine 1992;232:25–32. doi:10.1111/j.1365-2796.1992.tb00546.x.
7.
Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia. New England Journal of Medicine 2007;357:535–44. doi:10.1056/nejmoa067659.
8.
Kitchen S, Adcock DM, Dauer R, Kristoffersen A, Lippi G, Mackie I, et al. International Council for Standardization in Haematology (ICSH) recommendations for processing of blood samples for coagulation testing. International Journal of Laboratory Hematology 2021;43:1272–83. doi:10.1111/ijlh.13702.
9.
Kitchen S, Adcock DM, Dauer R, Kristoffersen A, Lippi G, Mackie I, et al. International Council for Standardisation in Haematology (ICSH) recommendations for collection of blood samples for coagulation testing. International Journal of Laboratory Hematology 2021;43:571–80. doi:10.1111/ijlh.13584.
10.
Kitchen S, Paula Careta F de, Lima Montalvão SA de, Gouider E, Kaczmarek R, Tagny CT, et al. WFH Guidelines for the Management of Hemophilia, 3rd Edition, Chapter 3: Laboratory diagnosis and monitoring. Haemophilia, Suppl 6:1-158 2020.
11.
Peyvandi F, Oldenburg J, Friedman KD. A critical appraisal of one‐stage and chromogenic assays of factor VIII activity. Journal of Thrombosis and Haemostasis 2016;14:248–61. doi:10.1111/jth.13215.
12.
Bowyer AE, Duncan EM, Antovic JP. Role of chromogenic assays in haemophilia A and B diagnosis. Haemophilia 2018;24:578–83. doi:10.1111/hae.13520.
13.
Zwagemaker A-F, Kloosterman FR, Gouw SC, Boyce S, Brons P, Cnossen MH, et al. Little discrepancy between one-stage and chromogenic factor VIII (FVIII)/IX assays in a large international cohort of persons with nonsevere hemophilia A and B. Journal of Thrombosis and Haemostasis 2023;21:850–61. doi:10.1016/j.jtha.2022.11.040.
14.
Kihlberg K, Strandberg K, Rosén S, Ljung R, Astermark J. Discrepancies between the one‐stage clotting assay and the chromogenic assay in haemophilia B. Haemophilia 2017;23:620–7. doi:10.1111/hae.13219.
15.
Meijer P, Peyvandi F, Young G, Pruthi R, Lima Montalvão S de, Kitchen S. International Council for Standardization in Haematology recommendations for laboratory measurement of factor VIII and FIX type I inhibitors. International Journal of Laboratory Hematology 2023;45:413–24. doi:10.1111/ijlh.14109.
16.
Potgieter JJ, Damgaard M, Hillarp A. One‐stage vs. chromogenic assays in haemophilia A. European Journal of Haematology 2015;94:38–44. doi:10.1111/ejh.12500.
17.
Müller J, Miesbach W, Prüller F, Siegemund T, Scholz U, Sachs UJ. An Update on Laboratory Diagnostics in Haemophilia A and B. Hämostaseologie 2022;42:248–60. doi:10.1055/a-1665-6232.
18.
Adcock DM, Strandberg K, Shima M, Marlar RA. Advantages, disadvantages and optimization of one‐stage and chromogenic factor activity assays in haemophilia A and B. International Journal of Laboratory Hematology 2018;40:621–9. doi:10.1111/ijlh.12877.
19.
Müller J, Goldmann G, Marquardt N, Pötzsch B, Oldenburg J. Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management. Hämostaseologie 2020;40:S15–20. doi:10.1055/a-1282-2251.
20.
Augustsson C, Norström E, Lind V, Martin M, Astermark J, Strandberg K. Validation of factor VIII activity for monitoring standard and extended half‐life products and correlation to thrombin generation assays. Haemophilia 2021;27:494–500. doi:10.1111/hae.14317.
21.
Gomez K, Laffan M, Keeney S, Sutherland M, Curry N, Lunt P. Recommendations for the clinical interpretation of genetic variants and presentation of results to patients with inherited bleeding disorders. A UK Haemophilia Centre Doctors’ Organisation Good Practice Paper. Haemophilia 2019;25:116–26. doi:10.1111/hae.13637.
22.
Lakich D, Kazazian HH, Antonarakis SE, Gitschier J. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nature Genetics 1993;5:236–41. doi:10.1038/ng1193-236.
23.
CDC. CDC Hemophilia Mutation Project databasesCHAMP/CHBMP (https://www.cdc.gov/ncbddd/hemophilia/champs.html) n.d.
24.
EAHAD. The European EAHAD Coagulation Factor Variant Databases (http://dbs.eahad.org) n.d.
25.
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine 2015;17:405–24. doi:10.1038/gim.2015.30.
26.
Manderstedt E, Nilsson R, Ljung R, Lind‐Halldén C, Astermark J, Halldén C. Detection of mosaics in hemophilia A by deep Ion Torrent sequencing and droplet digital PCR. Research and Practice in Thrombosis and Haemostasis 2020;4:1121–30. doi:10.1002/rth2.12425.
27.
Manderstedt E, Lind‐Halldén C, Ljung R, Astermark J, Halldén C. Detection of F8 int22h inversions using digital droplet PCR and mile‐post assays. Journal of Thrombosis and Haemostasis 2020;18:1039–49. doi:10.1111/jth.14760.
28.
Leuer M, Oldenburg J, Lavergne J-M, Ludwig M, Fregin A, Eigel A, et al. Somatic Mosaicism in Hemophilia A: A Fairly Common Event. The American Journal of Human Genetics 2001;69:75–87. doi:10.1086/321285.
29.
Green PM, Saad S, Lewis CM, Giannelli F. Mutation Rates in Humans. I. Overall and Sex-Specific Rates Obtained from a Population Study of Hemophilia B. The American Journal of Human Genetics 1999;65:1572–9. doi:10.1086/302651.
30.
Lavery S. Preimplantation genetic diagnosis of haemophilia. British Journal of Haematology 2009;144:303–7. doi:10.1111/j.1365-2141.2008.07391.x.
31.
Laurie AD, Hill AM, Harraway JR, Fellowes AP, Phillipson GT, Benny PS, et al. Preimplantation genetic diagnosis for hemophilia A using indirect linkage analysis and direct genotyping approaches. Journal of Thrombosis and Haemostasis 2010;8:783–9. doi:10.1111/j.1538-7836.2010.03768.x.
32.
Fischer K, Steen Carlsson K, Petrini P, Holmström M, Ljung R, Berg HM van den, et al. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: Comparing outcome and costs since the 1970s. Blood 2013;122:1129–36. doi:10.1182/blood-2012-12-470898.
33.
Steen Carlsson K, Höjgård S, Glomstein A, Lethagen S, Schulman S, Tengborn L, et al. On‐demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia 2003;9:555–66. doi:10.1046/j.1365-2516.2003.00817.x.
34.
Berntorp E, Astermark J, Baghaei F, Bergqvist D, Holmström M, Ljungberg B, et al. Treatment of haemophilia A and B and von Willebrand’s disease: summary and conclusions of a systematic review as part of a Swedish health‐technology assessment. Haemophilia 2011;18:158–65. doi:10.1111/j.1365-2516.2011.02723.x.
35.
Peyvandi F, Mannucci PM, Garagiola I, El-Beshlawy A, Elalfy M, Ramanan V, et al. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. New England Journal of Medicine 2016;374:2054–64. doi:10.1056/nejmoa1516437.
36.
Königs C, Ozelo M, Dunn A, Kulkarni R, Nolan B, Brown S, et al. Final results of PUPs A-LONG study: evaluating safety and efficacy of rFVIIIFc in previously untreated patients with haemophilia A. Res Pract Thromb Haemost 2020;4:8.
37.
Berntorp E, Andersson N. Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products. Seminars in Thrombosis and Hemostasis 2016;42:518–25. doi:10.1055/s-0036-1571315.
38.
Nolan B, Klukowska A, Shapiro A, Rauch A, Recht M, Ragni M, et al. Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B. Blood Advances 2021;5:2732–9. doi:10.1182/bloodadvances.2020004085.
39.
Hassan E, Jonathan L, Jayashree M. Real‐world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors. Haemophilia 2021;27. doi:10.1111/hae.14432.
40.
Teo HKW, Wong WH, Lam JCM. Recurrent intracranial bleed in a child receiving prophylaxis with emicizumab. Haemophilia 2021;27. doi:10.1111/hae.14274.
41.
Nijdam A, Kurnik K, Liesner R, Ljung R, Nolan B, Petrini P, et al. How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access. Haemophilia 2015;21:444–50. doi:10.1111/hae.12613.
42.
Andersson NG, Auerswald G, Barnes C, Carcao M, Dunn AL, Fijnvandraat K, et al. Intracranial haemorrhage in children and adolescents with severe haemophilia A or B – the impact of prophylactic treatment. British Journal of Haematology 2017;179:298–307. doi:10.1111/bjh.14844.
43.
Vepsäläinen K, Lassila R, Arola M, Lähteenmäki P, Möttönen M, Mäkipernaa A, et al. Complications associated with central venous access device in children with haemophilia: a nationwide multicentre study in Finland. Haemophilia 2015;21:747–53. doi:10.1111/hae.12665.
44.
Khair K, Ranta S, Thomas A, Lindvall K. The impact of clinical practice on the outcome of central venous access devices in children with haemophilia. Haemophilia 2017;23. doi:10.1111/hae.13241.
45.
Maclean PS, RichardsI M, Williams M, Collins P, Liesner R, Keeling DM, et al. Treatment related factors and inhibitor development in children with severe haemophilia A. Haemophilia 2010;17:282–7. doi:10.1111/j.1365-2516.2010.02422.x.
46.
Gouw SC, Bom JG van der, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007;109:4648–54. doi:10.1182/blood-2006-11-056291.
47.
Gouw SC, Berg HM van den, Fischer K, Auerswald G, Carcao M, Chalmers E, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013;121:4046–55. doi:10.1182/blood-2012-09-457036.
48.
Vepsäläinen K, Lassila R, Arola M, Huttunen P, Koskinen S, Ljung R, et al. Inhibitor development in previously untreated patients with severe haemophilia A: a nationwide multicentre study in Finland. Haemophilia 2016;22:721–9. doi:10.1111/hae.12974.
49.
Feldman BM, Funk SM, Bergstrom B, Zourikian N, Hilliard P, Net J van der, et al. Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: Validity of the hemophilia joint health score. Arthritis Care &Amp; Research 2011;63:223–30. doi:10.1002/acr.20353.
50.
Pettersson H, Ahlberg Å, Nilsson IM. A Radiologic Classification of Hemophilic Arthropathy. Clinical Orthopaedics and Related Research 1980;149:153???159. doi:10.1097/00003086-198006000-00018.
51.
Chan MW, Leckie A, Xavier F, Uleryk E, Tadros S, Blanchette V, et al. A systematic review of MR imaging as a tool for evaluating haemophilic arthropathy in children. Haemophilia 2013;19:e324–34. doi:10.1111/hae.12248.
52.
Lundin B, Manco‐Johnson ML, Ignas DM, Moineddin R, Blanchette VS, Dunn AL, et al. An MRI scale for assessment of haemophilic arthropathy from the International Prophylaxis Study Group. Haemophilia 2012;18:962–70. doi:10.1111/j.1365-2516.2012.02883.x.
53.
Kulkarni R. Comprehensive care of the patient with haemophilia and inhibitors undergoing surgery: Practical aspects. Haemophilia 2012;19:2–10. doi:10.1111/j.1365-2516.2012.02922.x.
54.
Ingerslev J, Hvid I. Surgery in Hemophilia. The General View: Patient Selection, Timing, and Preoperative Assessment. Seminars in Hematology 2006;43:S23–6. doi:10.1053/j.seminhematol.2005.11.024.
55.
Holme PA, Tjønnfjord GE, Batorova A. Continuous infusion of coagulation factor concentrates during intensive treatment. Haemophilia 2017;24:24–32. doi:10.1111/hae.13331.
56.
Srivastava A, Brewer AK, Mauser‐Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. Guidelines for the management of hemophilia. Haemophilia 2012;19. doi:10.1111/j.1365-2516.2012.02909.x.
57.
Ljung RCR, Knobe K. How to manage invasive procedures in children with haemophilia. British Journal of Haematology 2012;157:519–28. doi:10.1111/j.1365-2141.2012.09089.x.
58.
Hermans C, Altisent C, Batorova A, Chambost H, Moerloose P de, Karafoulidou A, et al. Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations. Haemophilia 2009;15:639–58. doi:10.1111/j.1365-2516.2008.01950.x.
59.
Coppola A, Castaman G, Santoro RC, Mancuso ME, Franchini M, Marino R, et al. Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Haemophilia 2020;26:937–45. doi:10.1111/hae.14172.
60.
Tjønnfjord GE, Brinch L, Gedde-Dahl T, Brosstad FR. Activated prothrombin complex concentrate (FEIBA®) treatment during surgery in patients with inhibitors to FVIII/IX: APCC FOR HAEMOPHILIACS DURING SURGERY. Haemophilia 2004;10:174–8. doi:10.1046/j.1365-2516.2003.00857.x.
61.
Dargaud Y, Lienhart A, Negrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood 2010;116:5734–7. doi:10.1182/blood-2010-06-291906.
62.
Holmström M, Tran HTT, Holme PA. Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A – a two‐centre experience. Haemophilia 2012;18:544–9. doi:10.1111/j.1365-2516.2012.02748.x.
63.
Rangarajan S, Austin S, Goddard NJ, Négrier C, Rodriguez‐Merchan EC, Stephensen D, et al. Consensus recommendations for the use of FEIBA® in haemophilia A patients with inhibitors undergoing elective orthopaedic and non‐orthopaedic surgery. Haemophilia 2012;19:294–303. doi:10.1111/hae.12028.
64.
Holme P, Tran H, Paus A, Tjonnfjord G. Surgery in haemophilia patients with inhibitors to FVIII/FIX: the Norwegian single centre study (O-WE-028). Journal of Thrombosis and Haemostasis 2011;9 (Suppl 2):512. doi:10.1111/j.1538-7836.2011.04380_3.x.
65.
Teitel JM, Carcao M, Lillicrap D, Mulder K, Rivard GE, St‐Louis J, et al. Orthopaedic surgery in haemophilia patients with inhibitors: A practical guide to haemostatic, surgical and rehabilitative care. Haemophilia 2009;15:227–39. doi:10.1111/j.1365-2516.2008.01840.x.
66.
Gilchrist G, Hoots WK, Cooper H, Gastineau D, Shapiro A. Prospective, Randomised Trial of Two Doses of rFVIIa (NovoSeven) in Haemophilia Patients with Inhibitors Undergoing Surgery. Thrombosis and Haemostasis 1998;80:773–8. doi:10.1055/s-0037-1615357.
67.
Mathew P, Valentino L, Sumner M, Seremetis S, Hoots K, Pruthi R. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery: Results from an open-label, randomized, multicenter trial. Thrombosis and Haemostasis 2007;98:726–32. doi:10.1160/th07-03-0198.
68.
Valentino LA, Cooper DL, Goldstein B. Surgical Experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX: SURGICAL EXPERIENCE WITH RFVIIA IN HAEMOPHILIA. Haemophilia 2011;17:579–89. doi:10.1111/j.1365-2516.2010.02460.x.
69.
Makris M, Hay CRM, Gringeri A, D’Oiron R. How I treat inhibitors in haemophilia. Haemophilia 2012;18:48–53. doi:10.1111/j.1365-2516.2012.02829.x.
70.
Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nature Medicine 2012;18:1570–4. doi:10.1038/nm.2942.
71.
Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. New England Journal of Medicine 2017;377:809–18. doi:10.1056/nejmoa1703068.
72.
Collins PW, Liesner R, Makris M, Talks K, Chowdary P, Chalmers E, et al. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee. Haemophilia 2018;24:344–7. doi:10.1111/hae.13495.
73.
Jiménez-Yuste V, Rodrı́guez-Merchán EC, Matsushita T, Holme PA. Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery. Haemophilia 2021;27:519–30. doi:10.1111/hae.14322.
74.
Lewandowska M, Randall N, Bakeer N, Maahs J, Sagar J, Greist A, et al. Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real‐world experience from a large comprehensive treatment centre in the US. Haemophilia 2020;27:90–9. doi:10.1111/hae.14212.
75.
Krumb E, Fijnvandraat K, Makris M, Peyvandi F, Ryan A, Athanasopoulos A, et al. Adoption of emicizumab (Hemlibra®) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey. Haemophilia 2021;27:736–43. doi:10.1111/hae.14372.
76.
Mahlangu JN, Andreeva TA, Macfarlane DE, Walsh C, Key NS. Recombinant B‐domain‐deleted porcine sequence factor VIII (r‐pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors. Haemophilia 2016;23:33–41. doi:10.1111/hae.13108.
77.
Croteau SE, Abajas YL, Wolberg AS, Nielsen BI, Marx GR, Baird CW, et al. Recombinant porcine factor VIII for high‐risk surgery in paediatric congenital haemophilia A with high‐titre inhibitor. Haemophilia 2017;23. doi:10.1111/hae.13157.
78.
Franchini M, Mannucci PM. Co‐morbidities and quality of life in elderly persons with haemophilia. British Journal of Haematology 2010;148:522–33. doi:10.1111/j.1365-2141.2009.08005.x.
79.
Khleif AA, Rodriguez N, Brown D, Escobar MA. Multiple Comorbid Conditions among Middle-Aged and Elderly Hemophilia Patients: Prevalence Estimates and Implications for Future Care. Journal of Aging Research 2011;2011:1–8. doi:10.4061/2011/985703.
80.
Marchesini E, Oliovecchio E, Coppola A, Santagostino E, Radossi P, Castaman G, et al. Comorbidities in persons with haemophilia aged 60 years or more compared with age‐matched people from the general population. Haemophilia 2017;24. doi:10.1111/hae.13379.
81.
Miesbach W, Reitter‐Pfoertner S‐E, Klamroth R, Langer F, Wolf H‐H, Tiede A, et al. Co‐morbidities and bleeding in elderly patients with haemophilia—A survey of the German, Austrian and Swiss Society of Thrombosis and Haemostasis Research (GTH). Haemophilia 2017;23:721–7. doi:10.1111/hae.13296.
82.
Harrison C, Saccullo G, Makris M. Haemophilia of the third age. Haemophilia 2018;24:15–6. doi:10.1111/hae.13257.
83.
Hollingdrake O, Mutch A, Zeissink B, Lawler SP, David M, Fitzgerald L. Haemophilia and age‐related comorbidities: Do men with haemophilia consult a general practitioner for men’s preventative health checks? Haemophilia 2016;22. doi:10.1111/hae.12968.
84.
Boccalandro E, Mancuso ME, Riva S, Pisaniello DM, Ronchetti F, Santagostino E, et al. Ageing successfully with haemophilia: A multidisciplinary programme. Haemophilia 2017;24:57–62. doi:10.1111/hae.13308.
85.
Stephensen D, Rodriguez‐Merchan EC. Orthopaedic co‐morbidities in the elderly haemophilia population: A review. Haemophilia 2012;19:166–73. doi:10.1111/hae.12006.
86.
Mannucci PM, Schutgens REG, Santagostino E, Mauser-Bunschoten EP. How I treat age-related morbidities in elderly persons with hemophilia. Blood 2009;114:5256–63. doi:10.1182/blood-2009-07-215665.
87.
Konkle BA. The aging patient with hemophilia. American Journal of Hematology 2012;87. doi:10.1002/ajh.23161.
88.
Konkle BA, Kessler C, Aledrot L, Andersen J, Fogarty P, Kouides P, et al. Emerging clinical concerns in the ageing haemophilia patient. Haemophilia 2009;15:1197–209. doi:10.1111/j.1365-2516.2009.02066.x.
89.
Isfordink CJ, Erpecum KJ van, Valk M van der, Mauser‐Bunschoten EP, Makris M. Viral hepatitis in haemophilia: Historical perspective and current management. British Journal of Haematology 2021;195:174–85. doi:10.1111/bjh.17438.
90.
Coppola A, Franchini M, Mannucci C, Mogavero S, Molinari A, Schinco P, et al. Emerging Issues on Comprehensive Hemophilia Care: Preventing, Identifying, and Monitoring Age-Related Comorbidities. Seminars in Thrombosis and Hemostasis 2013;39:794–802. doi:10.1055/s-0033-1354424.
91.
Dolan G. The challenge of an ageing haemophilic population. Haemophilia 2010;16:11–6. doi:10.1111/j.1365-2516.2010.02287.x.
92.
Coppola A, Tagliaferri A, Franchini M. The Management of Cardiovascular Diseases in Patients with Hemophilia. Seminars in Thrombosis and Hemostasis 2010;36:091–102. doi:10.1055/s-0030-1248728.
93.
Biere‐Rafi S, Tuinenburg A, Haak BW, Peters M, Huijgen R, Groot E de, et al. Factor VIII deficiency does not protect against atherosclerosis. Journal of Thrombosis and Haemostasis 2012;10:30–7. doi:10.1111/j.1538-7836.2011.04499.x.
94.
Schutgens REG, Tuinenburg A, Roosendaal G, Guyomi SH, Mauser‐Bunschoten EP. Treatment of ischaemic heart disease in haemophilia patients: An institutional guideline. Haemophilia 2009;15:952–8. doi:10.1111/j.1365-2516.2009.02020.x.
95.
Martin K, Key NS. How I treat patients with inherited bleeding disorders who need anticoagulant therapy. Blood 2016;128:178–84. doi:10.1182/blood-2015-12-635094.
96.
Schutgens REG, Jimenez-Yuste V, Escobar M, Falanga A, Gigante B, Klamroth R, et al. Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance. HemaSphere 2023;7:e900. doi:10.1097/hs9.0000000000000900.
97.
Bar-Chama N, Snyder S, Aledort L. Sexual evaluation and treatment of ageing males with haemophilia. Haemophilia 2011;17:875–83. doi:10.1111/j.1365-2516.2011.02507.x.
98.
Holme PA, Tait RC, Combescure C, Berntorp E, Tagliaferri A, Staritz P, et al. Renal Status and Hematuria in Older Patients with Hemophilia. Blood 2015;126:2290–0. doi:10.1182/blood.v126.23.2290.2290.
99.
Holme PA, Combescure C, Tait RC, Berntorp E, Rauchensteiner S, Moerloose P de. Hypertension, haematuria and renal functioning in haemophilia – a cross‐sectional study in Europe. Haemophilia 2015;22:248–55. doi:10.1111/hae.12847.
100.
Franchini M, Lippi G, Montagnana M, Targher G, Zaffanello M, Salvagno GL, et al. Hemophilia and cancer: A new challenge for hemophilia centers. Cancer Treatment Reviews 2009;35:374–7. doi:10.1016/j.ctrv.2009.01.001.
101.
Astermark J, Makris M, Mauser‐Bunschoten E, Nemes L, D’oiron R, Oldenburg J, et al. Malignant disease in the haemophilic population: Moving towards a management consensus? Haemophilia 2012;18:664–71. doi:10.1111/j.1365-2516.2012.02846.x.
102.
Fogarty PF, Kouides P. How we manage prostate biopsy and prostate cancer therapy in men with haemophilia. Haemophilia 2012;18. doi:10.1111/j.1365-2516.2012.02787.x.
103.
Moerloose P de, Fischer K, Lambert T, Windyga J, Batorova A, Lavigne‐Lissalde G, et al. Recommendations for assessment, monitoring and follow‐up of patients with haemophilia. Haemophilia 2011;18:319–25. doi:10.1111/j.1365-2516.2011.02671.x.
104.
Riley RR, Witkop M, Hellman E, Akins S. Assessment and management of pain in haemophilia patients: Pain in Haemophilia Patients. Haemophilia 2011;17:839–45. doi:10.1111/j.1365-2516.2011.02567.x.
105.
Humphries TJ, Kessler CM. The challenge of pain evaluation in haemophilia: Can pain evaluation and quantification be improved by using pain instruments from other clinical situations? Haemophilia 2012;19:181–7. doi:10.1111/hae.12023.
106.
Cheng OT, Souzdalnitski D, Vrooman B, Cheng J. Evidence-Based Knee Injections for the Management of Arthritis. Pain Medicine 2012;13:740–53. doi:10.1111/j.1526-4637.2012.01394.x.
107.
Steen Carlsson K, Winding B, Astermark J, Baghaei F, Brodin E, Funding E, et al. Pain, depression and anxiety in people with haemophilia from three Nordic countries: Cross‐sectional survey data from the MIND study. Haemophilia 2022;28:557–67. doi:10.1111/hae.14571.
108.
Kennedy M, O’ Mahony B, Roche S, McGowan M, Singleton E, Ryan K, et al. Pain and functional disability amongst adults with moderate and severe haemophilia from the Irish personalised approach to the treatment of haemophilia (iPATH) study. European Journal of Haematology 2022;108:518–27. doi:10.1111/ejh.13763.
109.
St‐Louis J, Abad A, Funk S, Tilak M, Classey S, Zourikian N, et al. The Hemophilia Joint Health Score version 2.1 Validation in Adult Patients Study: A multicenter international study. Research and Practice in Thrombosis and Haemostasis 2022;6:e12690. doi:10.1002/rth2.12690.
110.
McLaughlin P, Hurley M, Chowdary P, Khair K, Stephensen D. Physiotherapy interventions for pain management in haemophilia: A systematic review. Haemophilia 2020;26:667–84. doi:10.1111/hae.14030.
111.
Rodriguez-Merchan EC. Treatment of musculo-skeletal pain in haemophilia. Blood Reviews 2018;32:116–21. doi:10.1016/j.blre.2017.09.004.
112.
Gualtierotti R, Tafuri F, Arcudi S, Solimeno PL, Acquati J, Landi L, et al. Current and Emerging Approaches for Pain Management in Hemophilic Arthropathy. Pain and Therapy 2022;11:1–15. doi:10.1007/s40122-021-00345-x.
113.
Hughes LS, Clark J, Colclough JA, Dale E, McMillan D. Acceptance and Commitment Therapy (ACT) for Chronic Pain: A Systematic Review and Meta-Analyses. The Clinical Journal of Pain 2017;33:552–68. doi:10.1097/ajp.0000000000000425.
114.
Boccalandro EA, Begnozzi V, Garofalo S, Pasca S, Peyvandi F. The evolution of physiotherapy in the multidisciplinary management of persons with haemophilia (PWH): A scoping review. Haemophilia 2022;29:11–20. doi:10.1111/hae.14661.
115.
Lobet S, Timmer M, Königs C, Stephensen D, McLaughlin P, Duport G, et al. The Role of Physiotherapy in the New Treatment Landscape for Haemophilia. Journal of Clinical Medicine 2021;10:2822. doi:10.3390/jcm10132822.
116.
Wells A, Stephensen D. The role of the physiotherapist in the management of people with haemophilia: Defining the new normal. British Journal of Hospital Medicine 2020;81:1–8. doi:10.12968/hmed.2020.0016.
117.
Timmer MA, Blokzijl J, Schutgens REG, Veenhof C, Pisters MF. Coordinating physiotherapy care for persons with haemophilia. Haemophilia 2021;27:1051–61. doi:10.1111/hae.14404.
118.
Flannery T, Bladen M, Hopper D, Jones S, McLaughlin P, Penn A, et al. Physiotherapy after COVID‐19—"Zoom or room". Haemophilia 2020;27. doi:10.1111/hae.14166.
119.
Boccalandro EA, Dallari G, Mannucci PM. Telemedicine and telerehabilitation: Current and forthcoming applications in haemophilia. Blood Transfusion 2019:385–90. doi:10.2450/2019.0218-18.
120.
Wagner B, Seuser A, Krüger S, Herzig ML, Hilberg T, Ay C, et al. Establishing an online physical exercise program for people with hemophilia. Wiener Klinische Wochenschrift 2019;131:558–66. doi:10.1007/s00508-019-01548-1.
121.
O’Donovan M, Buckley C, Benson J, Roche S, McGowan M, Parkinson L, et al. Telehealth for delivery of haemophilia comprehensive care during the COVID‐19 pandemic. Haemophilia 2020;26:984–90. doi:10.1111/hae.14156.
122.
Mulder K, McCabe E, Strike K, Nilson J. Developing clinical practice guidelines for physiotherapists working with people with inherited bleeding disorders. Haemophilia 2021;27:674–82. doi:10.1111/hae.14327.
123.
Engelbert RHH, Plantinga M, Van der Net J, Van Genderen FR, Van den Berg MH, Helders PJM, et al. Aerobic Capacity in Children with Hemophilia. The Journal of Pediatrics 2008;152:833–838.e1. doi:10.1016/j.jpeds.2007.12.016.
124.
Tlacuilo‐Parra A, Morales‐Zambrano R, Tostado‐Rabago N, Esparza‐Flores MA, Lopez‐Guido B, Orozco‐Alcala J. Inactivity is a risk factor for low bone mineral density among haemophilic children. British Journal of Haematology 2008;140:562–7. doi:10.1111/j.1365-2141.2007.06972.x.
125.
Al-Sharif FA-G, Al-Jiffri OH, Abd El-Kader SM, Mohamed Ashmawy E. Impact of Mild versus Moderate Intensity Aerobic Walking Exercise Training on Markers of Bone Metabolism and Hand Grip Strength in Moderate Hemophilic A Patients. African Health Sciences 2014;14:11. doi:10.4314/ahs.v14i1.3.
126.
Gomis M, Querol F, Gallach JE, González LM, Aznar JA. Exercise and sport in the treatment of haemophilic patients: A systematic review. Haemophilia 2009;15:43–54. doi:10.1111/j.1365-2516.2008.01867.x.
127.
Runkel B, Von Mackensen S, Hilberg T. RCT – subjective physical performance and quality of life after a 6‐month programmed sports therapy (PST) in patients with haemophilia. Haemophilia 2016;23:144–51. doi:10.1111/hae.13079.
128.
Negrier C, Seuser A, Forsyth A, Lobet S, Llinas A, Rosas M, et al. The benefits of exercise for patients with haemophilia and recommendations for safe and effective physical activity. Haemophilia 2013;19:487–98. doi:10.1111/hae.12118.
129.
Runkel B, Czepa D, Hilberg T. RCT of a 6‐month programmed sports therapy (PST) in patients with haemophilia – Improvement of physical fitness. Haemophilia 2016;22:765–71. doi:10.1111/hae.12957.
130.
Wang M, Álvarez-Román MT, Chowdary P, Quon DV, Schafer K. Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports. Blood Coagulation & Fibrinolysis 2016;27:737–44. doi:10.1097/mbc.0000000000000565.
131.
Harris S, Boggio LN. Exercise may decrease further destruction in the adult haemophilic joint. Haemophilia 2006;12:237–40. doi:10.1111/j.1365-2516.2006.01214.x.
132.
Kennedy M, O’Gorman P, Monaghan A, Lavin M, O’Mahony B, O’Connell NM, et al. A systematic review of physical activity in people with haemophilia and its relationship with bleeding phenotype and treatment regimen. Haemophilia 2021;27:544–62. doi:10.1111/hae.14282.
133.
Heijnen L. The role of rehabilitation and sports in haemophilia patients with inhibitors. Haemophilia 2008;14:45–51. doi:10.1111/j.1365-2516.2008.01889.x.
134.
Beeton K, Kleijn P de, Hilliard P, Funk S, Zourikian N, Bergstrom B‐M, et al. Recent developments in clinimetric instruments. Haemophilia 2006;12:102–7. doi:10.1111/j.1365-2516.2006.01265.x.
135.
Di Minno M, Pasta G, Airaldi S, Zaottini F, Storino A, Cimino E, et al. Ultrasound for Early Detection of Joint Disease in Patients with Hemophilic Arthropathy. Journal of Clinical Medicine 2017;6:77. doi:10.3390/jcm6080077.
136.
Alberighi OD, Di Minno G, Graziano E, Molinari AC, Pasta G, Russo G, et al. Development and definition of a simplified scanning procedure and scoring method for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US). Thrombosis and Haemostasis 2013;109:1170–9. doi:10.1160/th12-11-0874.
137.
Stephensen D, Classey S, Harbidge H, Patel V, Taylor S, Wells A. Physiotherapist inter‐rater reliability of the Haemophilia Early Arthropathy Detection with Ultrasound protocol. Haemophilia 2018;24:471–6. doi:10.1111/hae.13440.
138.
Måseide RJ, Berntorp E, Astermark J, Hansen J, Olsson A, Bruzelius M, et al. Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) study. Haemophilia 2021;27. doi:10.1111/hae.14245.
139.
Hilliard P, Funk S, Zourikian N, Bergstrom B‐M, Bradley CS, McLimont M, et al. Hemophilia joint health score reliability study. Haemophilia 2006;12:518–25. doi:10.1111/j.1365-2516.2006.01312.x.
140.
Fischer K, Kleijn P de. Using the Haemophilia Joint Health Score for assessment of teenagers and young adults: exploring reliability and validity. Haemophilia 2013;19:944–50. doi:10.1111/hae.12197.
141.
Matlary RED, Grinda N, Sayers F, Versloot O, McLaughlin P. Promoting physical activity for people with haemophilia in the age of new treatments. Haemophilia 2022;28:885–90. doi:10.1111/hae.14641.
142.
Martin AP, Burke T, Asghar S, Noone D, Pedra G, O’Hara J. Understanding minimum and ideal factor levels for participation in physical activities by people with haemophilia: An expert elicitation exercise. Haemophilia 2020;26:711–7. doi:10.1111/hae.13985.
143.
Callahan LF, Brooks RH, Summey JA, Pincus T. Quantitative pain assessment for routine care of rheumatoid arthritis patients, using a pain scale based on activities of daily living and a visual analog pain scale. Arthritis &Amp; Rheumatism 1987;30:630–6. doi:10.1002/art.1780300605.
144.
Genderen FR van, Westers P, Heijnen L, Kleijn P de, Berg HM van den, Helders PJM, et al. Measuring patients’ perceptions on their functional abilities: validation of the Haemophilia Activities List. Haemophilia 2006;12:36–46. doi:10.1111/j.1365-2516.2006.01186.x.
145.
Poonnoose PM, Manigandan C, Thomas R, Shyamkumar NK, Kavitha ML, Bhattacharji S, et al. Functional Independence Score in Haemophilia: a new performance‐based instrument to measure disability. Haemophilia 2005;11:598–602. doi:10.1111/j.1365-2516.2005.01142.x.
146.
De la Corte-Rodriguez H, Rodriguez-Merchan EC. The Health Assessment Questionnaire Disability Index (HAQ-DI) as a valid alternative for measuring the functional capacity of people with haemophilia. Thrombosis Research 2017;153:51–6. doi:10.1016/j.thromres.2017.03.016.
147.
Gurcay E, Eksioglu E, Ezer U, Cakir B, Cakci A. A prospective series of musculoskeletal system rehabilitation of arthropathic joints in young male hemophilic patients. Rheumatology International 2007;28:541–5. doi:10.1007/s00296-007-0474-7.
148.
Hanley J, McKernan A, Creagh MD, Classey S, McLaughlin P, Goddard N, et al. Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia: A United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) guideline. Haemophilia 2017;23:511–20. doi:10.1111/hae.13201.
149.
Guodemar-Pérez J, Ruiz-López M, Rodríguez-López E, García-Fernández P, Hervás-Pérez JP. Physiotherapy Treatments in Musculoskeletal Pathologies Associated with Haemophilia: A literature review. Hämostaseologie 2018;38:141–9. doi:10.5482/hamo-16-11-0044.
150.
Neelapala YVR, Attal R, Tandale S. Aquatic exercise for persons with haemophilia: A review of literature. Complementary Therapies in Clinical Practice 2019;34:195–200. doi:10.1016/j.ctcp.2018.12.004.
151.
Young G, Tachdjian R, Baumann K, Panopoulos G. Comprehensive management of chronic pain in haemophilia. Haemophilia 2013;20. doi:10.1111/hae.12349.
152.
Strike K, Mulder K, Michael R. Exercise for haemophilia. Cochrane Database of Systematic Reviews 2016;2016. doi:10.1002/14651858.cd011180.pub2.
153.
Stephensen D, Bladen M, McLaughlin P. Recent advances in musculoskeletal physiotherapy for haemophilia. Therapeutic Advances in Hematology 2018;9:227–37. doi:10.1177/2040620718784834.
154.
Wagner B, Krüger S, Hilberg T, Ay C, Hasenoehrl T, Huber DF, et al. The effect of resistance exercise on strength and safety outcome for people with haemophilia: A systematic review. Haemophilia 2020;26:200–15. doi:10.1111/hae.13938.
155.
Tomschi F, Ransmann P, Hilberg T. Aerobic exercise in patients with haemophilia: A systematic review on safety, feasibility and health effects. Haemophilia 2022;28:397–408. doi:10.1111/hae.14522.
156.
Elshennawy S, Zahreldin AA, Mortada H, Hozien M, Youssef ASA, Galal A, et al. The Efficacy of Physical Therapy Modalities in Patients With Hemophilia: A Systematic Review of Randomized Controlled Trials With Meta-analysis. Archives of Physical Medicine and Rehabilitation 2023;104:475–89. doi:10.1016/j.apmr.2022.05.023.
157.
Kleijn P de, Blamey G, Zourikian N, Dalzell R, Lobet S. Physiotherapy following elective orthopaedic procedures. Haemophilia 2006;12:108–12. doi:10.1111/j.1365-2516.2006.01266.x.
158.
Escobar MA, Brewer A, Caviglia H, Forsyth A, Jimenez‐Yuste V, Laudenbach L, et al. Recommendations on multidisciplinary management of elective surgery in people with haemophilia. Haemophilia 2018;24:693–702. doi:10.1111/hae.13549.
159.
Heijnen L, Buzzard BB. The Role of Physical Therapy and Rehabilitation in the Management of Hemophilia in Developing Countries. Seminars in Thrombosis and Hemostasis 2005;31:513–7. doi:10.1055/s-2005-922222.
160.
Galen KPM van, d’Oiron R, James P, Abdul‐Kadir R, Kouides PA, Kulkarni R, et al. A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis 2021;19:1883–7. doi:10.1111/jth.15397.
161.
Plug I, Mauser-Bunschoten EP, Bröcker-Vriends AHJT, Amstel HKP van, Bom JG van der, Diemen-Homan JEM van, et al. Bleeding in carriers of hemophilia. Blood 2006;108:52–6. doi:10.1182/blood-2005-09-3879.
162.
Dowlut-McElroy T, Williams KB, Carpenter SL, Strickland JL. Menstrual Patterns and Treatment of Heavy Menstrual Bleeding in Adolescents with Bleeding Disorders. Journal of Pediatric and Adolescent Gynecology 2015;28:499–501. doi:10.1016/j.jpag.2015.03.001.
163.
Byams VR, Kouides PA, Kulkarni R, Baker JR, Brown DL, Gill JC, et al. Surveillance of female patients with inherited bleeding disorders in United States Haemophilia Treatment Centres. Haemophilia 2011;17:6–13. doi:10.1111/j.1365-2516.2011.02558.x.
164.
Pai M, Chan A, Barr R. How I manage heavy menstrual bleeding. British Journal of Haematology 2013;162:721–9. doi:10.1111/bjh.12447.
165.
Chaudhury A, Sidonio R, Jain N, Tsao E, Tymoszczuk J, Oviedo Ovando M, et al. Women and girls with haemophilia and bleeding tendencies: Outcomes related to menstruation, pregnancy, surgery and other bleeding episodes from a retrospective chart review. Haemophilia 2020;27:293–304. doi:10.1111/hae.14232.
166.
Alabek M, Mohan R, Raia M. Genetic counselling for hemophilia. Treatment of hemophilia monograph no. 25 2015.
167.
Dunn NF, Miller R, Griffioen A, Lee CA. Carrier testing in haemophilia A and B: adult carriers’ and their partners’ experiences and their views on the testing of young females. Haemophilia 2008;14:584–92. doi:10.1111/j.1365-2516.2007.01649.x.
168.
Street AM, Ljung R, Lavery SA. Management of carriers and babies with haemophilia. Haemophilia 2008;14:181–7. doi:10.1111/j.1365-2516.2008.01721.x.
169.
Chi C, Hyett J, Finning K, Lee C, Kadir R. Non‐invasive first trimester determination of fetal gender: A new approach for prenatal diagnosis of haemophilia. BJOG: An International Journal of Obstetrics &Amp; Gynaecology 2006;113:239–42. doi:10.1111/j.1471-0528.2006.00813.x.
170.
Mujezinovic F, Alfirevic Z. Procedure-Related Complications of Amniocentesis and Chorionic Villous Sampling: A Systematic Review. Obstetrics &Amp; Gynecology 2007;110:687–94. doi:10.1097/01.aog.0000278820.54029.e3.
171.
Rizza CR, Rhymes IL, Austen DEG, Kernoff PBA, Aroni SA. Detection of Carriers of Haemophilia: a “Blind” Study. British Journal of Haematology 1975;30:447–56. doi:10.1111/j.1365-2141.1975.tb01859.x.
172.
Chi C, Lee CA, Shiltagh N, Khan A, Pollard D, Kadir RA. Pregnancy in carriers of haemophilia. Haemophilia 2007;14:56–64. doi:10.1111/j.1365-2516.2007.01561.x.
173.
Dunkley S, Curtin JA, Marren AJ, Heavener RP, McRae S, Curnow JL. Updated Australian consensus statement on management of inherited bleeding disorders in pregnancy. Medical Journal of Australia 2019;210:326–32. doi:10.5694/mja2.50123.
174.
James AH, Konkle BA, Kouides P, Ragni MV, Thames B, Gupta S, et al. Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis. Haemophilia 2014;21:81–7. doi:10.1111/hae.12568.
175.
Chi C, Lee C, England A, Hingorani J, Paintsil J, Kadir R. Obstetric analgesia and anaesthesia in women with inherited bleeding disorders. Thrombosis and Haemostasis 2009;101:1104–11. doi:10.1160/th08-10-0694.
176.
Andersson NG, Chalmers EA, Kenet G, Ljung R, Mäkipernaa A, Chambost H. Mode of delivery in hemophilia: vaginal delivery and Cesarean section carry similar risks for intracranial hemorrhages and other major bleeds. Haematologica 2019;104:2100–6. doi:10.3324/haematol.2018.209619.
177.
Kletzel M. Postdelivery Head Bleeding in Hemophilic Neonates: Causes and Management. American Journal of Diseases of Children 1989;143:1107. doi:10.1001/archpedi.1989.02150210143035.
178.
Mauser-Bunschoten EP. Symptomatic carriers of hemophilia. Treatment of Hemophilia 2008;46:1–9.
179.
Girgis MR, Gusba L, Kuriakose P. Management of haemophilia carriers around the time of their delivery: Phenotypic variation requiring customization of management. Haemophilia 2018;24. doi:10.1111/hae.13448.
180.
Sentilhes L, Lasocki S, Ducloy-Bouthors AS, Deruelle P, Dreyfus M, Perrotin F, et al. Tranexamic acid for the prevention and treatment of postpartum haemorrhage. British Journal of Anaesthesia 2015;114:576–87. doi:10.1093/bja/aeu448.
181.
Chalmers E, Williams M, Brennand J, Liesner R, Collins P, Richards M. Guideline on the management of haemophilia in the fetus and neonate*. British Journal of Haematology 2011;154:208–15. doi:10.1111/j.1365-2141.2010.08545.x.
182.
Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020;26:1–158. doi:10.1111/hae.14046.
183.
Pollard D, Harrison C, Dodgson S, Holland M, Khair K. The UK haemophilia specialist nurse: Competencies fit for practice in the 21st century. Haemophilia 2020;26:622–30. doi:10.1111/hae.14002.
184.
Colvin BT, Astermark J, Fischer K, Gringeri A, Lassila R, Schramm W, et al. European principles of haemophilia care. Haemophilia 2008;14:361–74. doi:10.1111/j.1365-2516.2007.01625.x.
185.
Myrin Westesson L, Wallengren C, Baghaei F, Sparud-Lundin C. Reaching Independence Through Forced Learning: Learning Processes and Illness Management in Parents of Children Affected by Hemophilia. Qualitative Health Research 2018;28:2142–54. doi:10.1177/1049732318789631.
186.
Harrington C, Bedford M, Andritschke K, Barrie A, Elfvinge P, Grønhaug S, et al. A European curriculum for nurses working in haemophilia. Haemophilia 2015;22:103–9. doi:10.1111/hae.12785.
187.
DeKoven M, Karkare S, Kelley LA, Cooper DL, Pham H, Powers J, et al. Understanding the experience of caring for children with haemophilia: cross‐sectional study of caregivers in the United States. Haemophilia 2014;20:541–9. doi:10.1111/hae.12379.
188.
Petrini P. Identifying and overcoming barriers to prophylaxis in the management of haemophilia. Haemophilia 2007;13:16–22. doi:10.1111/j.1365-2516.2007.01501.x.
189.
Lindvall K, Mackensen S von, Elmståhl S, Khair K, Stain AM, Ljung R, et al. Increased burden on caregivers of having a child with haemophilia complicated by inhibitors. Pediatric Blood &Amp; Cancer 2013;61:706–11. doi:10.1002/pbc.24856.
190.
Galen K van, Lavin M, Skouw‐Rasmussen N, Fischer K, Noone D, Pollard D, et al. European principles of care for women and girls with inherited bleeding disorders. Haemophilia 2021;27:837–47. doi:10.1111/hae.14379.
191.
Aradom E, Gomez K. The patient gene therapy journey: Findings from qualitative interviews with trial participants at one UK haemophilia centre. The Journal of Haemophilia Practice 2021;8:32–44. doi:10.17225/jhp00174.
192.
Schrijvers LH, Beijlevelt‐van der Zande M, Peters M, Schuurmans MJ, Fischer K. Learning intravenous infusion in haemophilia: experience from the Netherlands. Haemophilia 2012;18:516–20. doi:10.1111/j.1365-2516.2012.02752.x.
193.
Schrijvers L, Beijlevelt-Van der Zande M, Peters M, Lock J, Cnossen M, Schuurmans M, et al. Achieving self-management of prophylactic treatment in adolescents: The case of haemophilia. Patient Education and Counseling 2016;99:1179–83. doi:10.1016/j.pec.2016.01.016.
194.
DeKoven M, Karkare S, Lee WC, Kelley LA, Cooper DL, Pham H, et al. Impact of haemophilia with inhibitors on caregiver burden in the United States. Haemophilia 2014;20:822–30. doi:10.1111/hae.12501.
195.
Zanon, Martinelli, Bacci, Zerbinati, Girolami. Proposal of a standard approach to dental extraction in haemophilia patients. A case‐control study with good results. Haemophilia 2000;6:533–6. doi:10.1046/j.1365-2516.2000.00423.x.
196.
Franchini M, Rossetti G, Tagliaferri A, Pattacini C, Pozzoli D, Lorenz C, et al. Dental procedures in adult patients with hereditary bleeding disorders: 10 years experience in three Italian Hemophilia Centers. Haemophilia 2005;11:504–9. doi:10.1111/j.1365-2516.2005.01132.x.
197.
Kalsi H, Nanayakkara L, Pasi KJ, Bowles L, Hart DP. Access to primary dental care for patients with inherited bleeding disorders. Haemophilia 2011;18:510–5. doi:10.1111/j.1365-2516.2011.02716.x.
198.
Lee APH, Boyle CA, Savidge GF, Fiske J. Effectiveness in controlling haemorrhage after dental scaling in people with haemophilia by using tranexamic acid mouthwash. British Dental Journal 2005;198:33–8. doi:10.1038/sj.bdj.4811955.
199.
Kennedy A, Sloman F, Douglass JA, Sawyer SM. Young people with chronic illness: The approach to transition. Internal Medicine Journal 2007;37:555–60. doi:10.1111/j.1445-5994.2007.01440.x.
200.
Breakey VR, Ignas DM, Warias AV, White M, Blanchette VS, Stinson JN. A pilot randomized control trial to evaluate the feasibility of an Internet‐based self‐management and transitional care program for youth with haemophilia. Haemophilia 2014;20:784–93. doi:10.1111/hae.12488.
201.
Adelman W, Braverman PK, Alderman EM, Breuner CC, Levine DA, Marcell AV, et al. Achieving Quality Health Services for Adolescents. Pediatrics 2016;138. doi:10.1542/peds.2016-1347.
202.
Bridgett M, Ho J, Brodie L, Towns S, Steinbeck K. 221. Transition, It’s More Than Just a Phase: A New Model of Care in Australia. Journal of Adolescent Health 2015;56:S113. doi:10.1016/j.jadohealth.2014.10.226.
203.
Great Britain. Transition: Getting it Right for Young People: Improving the Transition of Young People with Long Term Conditions from Children’s to Adult Health Services. Department of Health; 2006.
204.
White P, Schmidt A, Shorr J, Ilango S, Beck D, McManus M. Six core elements of health care transition™ 3.0. Washington, DC: Got Transition, The National Alliance to Advance Adolescent Health 2020.
205.
Kaufman M, Pinzon J. Transition to adult care for youth with special health care needs. Paediatrics &Amp; Child Health 2007;12:785–8. doi:10.1093/pch/12.9.785.
206.
Royal College of Nursing. Children and Young People: Transition to Adult Services. 2024.
207.
Agency for Clinical Innovation. Key principles for transition care. NSW Government; 2022.
208.
Betz CL. Transition of adolescents with special health care needs: Review and analysis of the literature. Issues in Comprehensive Pediatric Nursing 2004;27:179–241. doi:10.1080/01460860490497903.
209.
Hanghøj S, Boisen KA. Self-Reported Barriers to Medication Adherence Among Chronically Ill Adolescents: A Systematic Review. Journal of Adolescent Health 2014;54:121–38. doi:10.1016/j.jadohealth.2013.08.009.
210.
Transformation Partners in Health and Care. YOU’RE WELCOME PILOT 2017 - Refreshed Standards for Piloting. 2017.
211.
RACP Joint Adolescent Health Committee. Confidential Health Care for Adolescents and Young People (12–24 years). The Royal Australasian College of Physicians; 2010.
212.
Suris J-C, Akre C. Key Elements for, and Indicators of, a Successful Transition: An International Delphi Study. Journal of Adolescent Health 2015;56:612–8. doi:10.1016/j.jadohealth.2015.02.007.
213.
Colver A, Rapley T, Parr JR, McConachie H, Dovey-Pearce G, Couteur AL, et al. Facilitating transition of young people with long-term health conditions from children’s to adults’ healthcare services – implications of a 5-year research programme. Clinical Medicine 2020;20:74–80. doi:10.7861/clinmed.2019-0077.
214.
Thomsen EL, Hertz PG, Blix C, Boisen KA. Danske anbefalinger til et ungevenligt sundhedsvæsen. Fag & Forskning: Sygeplejersken 2020:52–7.
215.
Chadi N, Amaria K, Kaufman M. Expand your HEADS, follow the THRxEADS! Paediatrics &Amp; Child Health 2017;22:23–5. doi:10.1093/pch/pxw007.
216.
Lee Mortensen G, Strand AM, Almén L. Adherence to prophylactic haemophilic treatment in young patients transitioning to adult care: A qualitative review. Haemophilia 2018;24:862–72. doi:10.1111/hae.13621.
217.
Hanghøj S, Boisen KA, Schmiegelow K, Hølge-Hazelton B. Feasibility of a transition intervention aimed at adolescents with chronic illness. International Journal of Adolescent Medicine and Health 2016;30. doi:10.1515/ijamh-2016-0047.
218.
White PH, Cooley WC. Supporting the Health Care Transition From Adolescence to Adulthood in the Medical Home. Pediatrics 2018;142. doi:10.1542/peds.2018-2587.
219.
WFH. Guidelines for the Management of Hemophilia 3rd Edition: Comprehensive care of hemophilia. World Federation of Hemophilia; 2020.
220.
Gouw SC, Bom JG van der, Ljung R, Escuriola C, Cid AR, Claeyssens-Donadel S, et al. Factor VIII Products and Inhibitor Development in Severe Hemophilia A. New England Journal of Medicine 2013;368:231–9. doi:10.1056/nejmoa1208024.
221.
Abdi A, Eckhardt CL, Velzen AS van, Vuong C, Coppens M, Castaman G, et al. Treatment‐related risk factors for inhibitor development in non‐severe hemophilia A after 50 cumulative exposure days: A case‐control study. Journal of Thrombosis and Haemostasis 2021;19:2171–81. doi:10.1111/jth.15419.
222.
Kihlberg K, Baghaei F, Bruzelius M, Funding E, Andre Holme P, Lassila R, et al. Treatment outcomes in persons with severe haemophilia B in the Nordic region: The B‐NORD study. Haemophilia 2021;27:366–74. doi:10.1111/hae.14299.
223.
Male C, Andersson NG, Rafowicz A, Liesner R, Kurnik K, Fischer K, et al. Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study. Haematologica 2020;106:123–9. doi:10.3324/haematol.2019.239160.
224.
Andersson NG, Labarque V, Kartal-Kaess M, Pinto F, Mikkelsen TS, Ljung R, et al. Factor VIII genotype and the risk of developing high-responding or low-responding inhibitors in severe hemophilia A: data from the PedNet Hemophilia Cohort of 1,202 children. Haematologica 2023. doi:10.3324/haematol.2023.284095.
225.
Mannucci PM, Gringeri A, Peyvandi F, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma‐product exposed toddlers). Haemophilia 2007;13:65–8. doi:10.1111/j.1365-2516.2007.01580.x.
226.
Fischer K, Carcao M, Male C, Ranta S, Pergantou H, Kenet G, et al. Different inhibitor incidence for individual factor VIII concentrates in 1076 previously untreated patients with severe hemophilia A: data from the PedNet cohort. Journal of Thrombosis and Haemostasis 2023;21:700–3. doi:10.1016/j.jtha.2022.11.020.
227.
Fischer K, Iorio A, Hollingsworth R, Makris M. FVIII inhibitor development according to concentrate: data from the EUHASS registry excluding overlap with other studies. Haemophilia 2015;22. doi:10.1111/hae.12764.
228.
Berg HM van den, Fischer K, Carcao M, Chambost H, Kenet G, Kurnik K, et al. Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. Blood 2019;134:317–20. doi:10.1182/blood.2019000658.
229.
Frampton JE. Efmoroctocog Alfa: A Review in Haemophilia A. Drugs 2016;76:1281–91. doi:10.1007/s40265-016-0622-z.
230.
Mancuso ME, Fischer K, Santagostino E, Oldenburg J, Platokouki H, Königs C, et al. Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors. Thrombosis and Haemostasis 2017;117:2274–82. doi:10.1160/th17-01-0059.
231.
Ranta S, Motwani J, Blatny J, Bührlen M, Carcao M, Chambost H, et al. Dilemmas on emicizumab in children with haemophilia A: A survey of strategies from PedNet centres. Haemophilia 2023;29:1291–8. doi:10.1111/hae.14847.
232.
Kihlberg K, Baghaei F, Bruzelius M, Funding E, Holme PA, Lassila R, et al. Factor IX antibodies and tolerance in hemophilia B in the Nordic countries – The impact of F9 variants and complications. Thrombosis Research 2022;217:22–32. doi:10.1016/j.thromres.2022.06.015.
233.
Konkle BA, Ebbesen LS, Erhardtsen E, Bianco RP, Lissitchkov T, Rusen L, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. Journal of Thrombosis and Haemostasis 2007;5:1904–13. doi:10.1111/j.1538-7836.2007.02663.x.
234.
Antunes SV, Tangada S, Stasyshyn O, Mamonov V, Phillips J, Guzman‐Becerra N, et al. Randomized comparison of prophylaxis and on‐demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia 2013;20:65–72. doi:10.1111/hae.12246.
235.
Matsushita T, Shapiro A, Abraham A, Angchaisuksiri P, Castaman G, Cepo K, et al. Phase 3 Trial of Concizumab in Hemophilia with Inhibitors. New England Journal of Medicine 2023;389:783–94. doi:10.1056/nejmoa2216455.
236.
Kenet G, Nolan B, Zülfikar OB, Antmen B, Kampmann P, Matsushita T, et al. Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis (ATLAS-PPX). Blood Journal 2024. doi:10.1182/blood.2023021864.
237.
Young G, Srivastava A, Kavakli K, Ross C, Sathar J, You C-W, et al. Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial. The Lancet 2023;401:1427–37. doi:10.1016/s0140-6736(23)00284-2.
238.
Aymonnier K, Kawecki C, Arocas V, Boulaftali Y, Bouton MC. Serpins, New Therapeutic Targets for Hemophilia. Thrombosis and Haemostasis 2020;121:261–9. doi:10.1055/s-0040-1716751.
239.
Makris M, Iorio A, Lenting PJ. Emicizumab and thrombosis: The story so far. Journal of Thrombosis and Haemostasis 2019;17:1269–72. doi:10.1111/jth.14556.
240.
Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2006;109:546–51. doi:10.1182/blood-2006-04-017988.
241.
Young G, Shafer FE, Rojas P, Seremetis S. Single 270 μg kg- 1-dose rFVIIa vs. standard 90 μg kg- 1-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2007;14:287–94. doi:10.1111/j.1365-2516.2007.01601.x.
242.
Ingerslev J, Sørensen B. Parallel use of by‐passing agents in haemophilia with inhibitors: A critical review. British Journal of Haematology 2011;155:256–62. doi:10.1111/j.1365-2141.2011.08854.x.
243.
Abdi A, Linari S, Pieri L, Voorberg J, Fijnvandraat K, Castaman G. Inhibitors in Nonsevere Hemophilia A: What Is Known and Searching for the Unknown. Seminars in Thrombosis and Hemostasis 2018;44:568–77. doi:10.1055/s-0037-1621717.
244.
Eckhardt CL, Velzen AS van, Peters M, Astermark J, Brons PP, Castaman G, et al. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood 2013;122:1954–62. doi:10.1182/blood-2013-02-483263.
245.
Kempton CL, Allen G, Hord J, Kruse‐Jarres R, Pruthi RK, Walsh C, et al. Eradication of factor viii inhibitors in patients with mild and moderate hemophilia A. American Journal of Hematology 2012;87:933–6. doi:10.1002/ajh.23269.
246.
Castaman G, Eckhardt C, Velzen A van, Linari S, Fijnvandraat K. Emerging Issues in Diagnosis, Biology, and Inhibitor Risk in Mild Hemophilia A. Seminars in Thrombosis and Hemostasis 2016;42:507–12. doi:10.1055/s-0036-1571309.
247.
Oomen I, Camelo RM, Rezende SM, Voorberg J, Mancuso ME, Oldenburg J, et al. Determinants of successful immune tolerance induction in hemophilia A: systematic review and meta-analysis. Research and Practice in Thrombosis and Haemostasis 2023;7:100020. doi:10.1016/j.rpth.2022.100020.
248.
Brackmann HH, Gormsen J. MASSIVE FACTOR-VIII INFUSION IN HÆMOPHILIAC WITH FACTOR-VIII INHIBITOR, HIGH RESPONDER. The Lancet 1977;310:933. doi:10.1016/s0140-6736(77)90871-6.
249.
Hay CRM, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012;119:1335–44. doi:10.1182/blood-2011-08-369132.
250.
Velzen AS van, Peters M, Bom JG van der, Fijnvandraat K. Effect of von Willebrand factor on inhibitor eradication in patients with severe haemophilia A: a systematic review. British Journal of Haematology 2014;166:485–95. doi:10.1111/bjh.12942.
251.
Malec L, Van Damme A, Chan AKC, Spasova M, Jain N, Sensinger C, et al. Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study. Blood 2023;141:1982–9. doi:10.1182/blood.2022017780.
252.
Hauch H, Rischewski J, Kordes U, Schneppenheim J, Schneppenheim R, Beutel K. ITI with high-dose FIX and combined immunosuppressive therapy in a patient with severe haemophilia B and inhibitor. Hämostaseologie 2009;29:155–7. doi:10.1055/s-0037-1617018.
253.
Berntorp E, Astermark J, Carlborg E. Immune tolerance induction and the treatment of hemophilia. Malmö protocol update. Haematologica 2000;85:48-50; discussion 50-1.
254.
Wallny TA, Scholz DT, Oldenburg J, Nicolay C, Ezziddin S, Pennekamp PH, et al. Osteoporosis in haemophilia – an underestimated comorbidity? Haemophilia 2006;13:79–84. doi:10.1111/j.1365-2516.2006.01405.x.
255.
Gerstner G, Damiano ML, Tom A, Worman C, Schultz W, Recht M, et al. Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia. Haemophilia 2009;15:559–65. doi:10.1111/j.1365-2516.2008.01963.x.
256.
Bull FC, Al-Ansari SS, Biddle S, Borodulin K, Buman MP, Cardon G, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. British Journal of Sports Medicine 2020;54:1451–62. doi:10.1136/bjsports-2020-102955.
257.
Pipe SW, Gonen-Yaacovi G, Segurado OG. Hemophilia A gene therapy: current and next-generation approaches. Expert Opinion on Biological Therapy 2022;22:1099–115. doi:10.1080/14712598.2022.2002842.
258.
Mancuso ME, Mahlangu JN, Pipe SW. The changing treatment landscape in haemophilia: From standard half-life clotting factor concentrates to gene editing. The Lancet 2021;397:630–40. doi:10.1016/s0140-6736(20)32722-7.
259.
Astermark J, Baghaei F, Strandberg K, Toplican PG, Birkedal MF, Grahn EE, et al. Infrastructural considerations of implementing gene therapy for hemophilia in the Nordic context. Therapeutic Advances in Hematology 2023;14. doi:10.1177/20406207231202306.
260.
Pasi KJ, Rangarajan S, Mitchell N, Lester W, Symington E, Madan B, et al. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A. New England Journal of Medicine 2020;382:29–40. doi:10.1056/nejmoa1908490.
261.
Pipe SW, Leebeek FWG, Recht M, Key NS, Castaman G, Miesbach W, et al. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. New England Journal of Medicine 2023;388:706–18. doi:10.1056/nejmoa2211644.
262.
Miesbach W, O’Mahony B, Key NS, Makris M. How to discuss gene therapy for haemophilia? A patient and physician perspective. Haemophilia 2019;25:545–57. doi:10.1111/hae.13769.
263.
Miesbach W, Oldenburg J, Klamroth R, Eichler H, Koscielny J, Holzhauer S, et al. Gentherapie der Hämophilie: Empfehlung der Gesellschaft für Thrombose- und Hämostaseforschung (GTH). Hämostaseologie 2022;43:196–207. doi:10.1055/a-1957-4477.
264.
Miesbach W, Chowdary P, Coppens M, Hart DP, Jimenez‐Yuste V, Klamroth R, et al. Delivery of AAV‐based gene therapy through haemophilia centres—A need for re‐evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC. Haemophilia 2021;27:967–73. doi:10.1111/hae.14420.
265.
Miesbach W, Foster GR, Peyvandi F. Liver-related aspects of gene therapy for haemophilia: Call to action for collaboration between haematologists and hepatologists. Journal of Hepatology 2023;78:467–70. doi:10.1016/j.jhep.2022.11.014.